Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-11 17:51 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Cimzia Versus Mesalamine for Crohn's Recurrence
NCT01696942 · Milton S. Hershey Medical Center · PHASE4 · terminated · last registry update 2018-01-12 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “Lack of accrual” | – | Registry record, Milton S. Hershey Medical Center |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against TNF within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2018-10-16Phase 3 first posted: Celltrion, CT-P13 + Remicade (NCT03707535)
- 2018-10-16Results posted on the registry: UCB Pharma SA, Certolizumab Pegol (NCT02319642)
- 2018-10-15Phase 3 first posted: Assistance Publique - Hôpitaux de Paris, Infliximab + Placebo (NCT03704610)
- 2018-10-12Phase 3 first posted: Oslo University Hospital, Biosimilar Infliximab (NCT03704363)
- 2018-10-09Also stopped (withdrawn): Bristol-Myers Squibb, Infliximab + Prednisone + Methylprednisolone + Prednisone (NCT02763761)
- 2018-10-01Results posted on the registry: Janssen Research & Development, LLC, Placebo + Ustekinumab 45 mg (NCT02438787)
- 2018-09-26Results posted on the registry: Tanabe Pharma Corporation, TA-650 + Polyethylene Glycol-treated Human Immunoglobulin (VGIH) (NCT01596335)
- 2018-08-20Results posted on the registry: Merck Sharp & Dohme LLC, Golimumab (NCT02318667)
- 2018-08-13Results posted on the registry: UCB Biopharma S.P.R.L., Certolizumab Pegol (NCT02326298)
- 2018-08-13Results posted on the registry: UCB Biopharma S.P.R.L., Certolizumab Pegol (NCT02326272)
- 2018-08-09Also stopped (terminated): UCB Pharma, certolizumab pegol 400 mg (NCT00349752)
- 2018-08-07Also stopped (terminated): UCB Celltech, Certolizumab Pegol + Certolizumab Pegol (NCT00899678)
- 2018-08-01Also stopped (terminated): UCB Pharma, Certolizumab Pegol (NCT01292265)
- 2018-07-24Phase 3 first posted: Janssen Research & Development, LLC, Golimumab + Infliximab (NCT03596645)
- 2018-07-18Results posted on the registry: UCB Biopharma S.P.R.L., Certolizumab Pegol + Etanercept (NCT02346240)
- 2018-06-27Results posted on the registry: Gilead Sciences, Andecaliximab + Placebo (NCT02862574)
- 2018-06-27Also stopped (terminated): Gilead Sciences, Andecaliximab + Placebo (NCT02862574)
- 2018-04-23Results posted on the registry: Janssen Research & Development, LLC, Placebo + Ustekinumab 45 mg (NCT02437162)
- 2018-04-11Results posted on the registry: Celltrion, CT-P13 + Remicade (NCT02096861)
- 2018-03-27Phase 3 first posted: Shanghai Biomabs Pharmaceutical Co., Ltd., CMAB008 + MTX (NCT03478111)
- 2018-03-22Results posted on the registry: ICStudy, LLC, Certolizumab pegol + Placebo (NCT02497976)
- 2018-03-20Results posted on the registry: UCB Pharma SA, Belgium, Certolizumab Pegol + Methotrexate (NCT02151851)
- 2018-02-08Results posted on the registry: Herbert Lindsley, MD, Infliximab + Placebo (NCT01144143)
- 2018-01-30Phase 3 first posted: University of Nebraska, Methotrexate + Abatacept (NCT03414502)
- 2018-01-08Also stopped (withdrawn): University of Arkansas, a drug against TNF (NCT02729233)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision